SACHS BRUCE I 4

What Happened Bruce I. Sachs, a director of Vertex Pharmaceuticals (VRTX), received an award of 99.941 deferred stock units (DSUs) on July 15, 2026. The award is recorded at $475.28 per unit, with a reported aggregate value of $47,500. The filing classifies this as an acquisition via award (transaction code A) of a derivative instrument rather than an immediate share purchase.

Key Details

• Transaction date: July 15, 2026; Form 4 filed July 17, 2026 (appears filed within the normal 2-business-day window).
• Instrument: 99.941 deferred stock units (derivative), price/value per unit $475.28, total value $47,500.
• Transaction code: A (award/grant/acquisition).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote: Each deferred stock unit represents one share of common stock and will be paid out in common stock upon the earliest of (i) Mr. Sachs’ termination of board service, (ii) a change of control, or (iii) Mr. Sachs’ disability or death.

Context Deferred stock units are a form of director compensation that convert into actual shares only upon specified events; they are not an immediate open-market purchase and therefore do not directly signal a near-term market bet by the insider. Such awards are routine for board members and are typically part of standard compensation arrangements.